Tolvaptan
- Generic Name
- Tolvaptan
- Brand Names
- Jinarc, Jynarque 45/15 Carton, Samsca, Tolvaptan Accord, Xeljanz
- Drug Type
- Small Molecule
- Chemical Formula
- C26H25ClN2O3
- CAS Number
- 150683-30-0
- Unique Ingredient Identifier
- 1E2497LPNY
- Background
Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.
- Indication
Treatment of symptomatic and resistant to fluid restriction euvolemic or hypervolemic hyponatremia associated with congestive heart failure, SIADH, and cirrhosis.
- Associated Conditions
- Autosomal Dominant Polycystic Kidney Disease （ADPKD), Symptomatic euvolemic Hyponatremia, Symptomatic hypervolemic Hyponatremia
- Associated Therapies
- -
Effects of Tofacitinib on Body Composition, Bone Mineral Density and Bone Marrow Adiposity in Patients With Rheumatoid Arthritis: the TOFAT Project
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- University Hospital, Lille
- Target Recruit Count
- 10
- Registration Number
- NCT04175886
- Locations
- 🇫🇷
Lille University Hospital, Lille, France
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT04034238
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis
- First Posted Date
- 2019-06-11
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 314
- Registration Number
- NCT03981900
- Locations
- 🇫🇷
Cabinet Medical, Vincennes, France
🇫🇷Centre Hospitalier D Auxerre, Auxerre, France
🇫🇷Institut Calot Helio Marin, Berck Sur Mer, France
Advanced Therapeutics in Rheumatoid Arthritis (RA)
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Lawson Health Research Institute
- Target Recruit Count
- 144
- Registration Number
- NCT03976245
- Locations
- 🇨🇦
Rheumatology Clinic, St. Joseph's Health Care, London, Ontario, Canada
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)
- Conditions
- Interventions
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1764
- Registration Number
- NCT03970837
- Locations
- 🇬🇧
GSK Investigational Site, Kenilworth, Warwickshire, United Kingdom
Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2019-05-14
- Last Posted Date
- 2022-06-16
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT03949894
- Locations
- 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Kosin University Gospel Hospital, Busan, Korea, Republic of
Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD
- Conditions
- Interventions
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2019-01-14
- Lead Sponsor
- Regional Hospital Holstebro
- Target Recruit Count
- 20
- Registration Number
- NCT03803124
- Locations
- 🇩🇰
Departments of medical research and medicine, Holstebro, Denmark
Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Institute of Dermatology, Thailand
- Target Recruit Count
- 19
- Registration Number
- NCT03800979
- Locations
- 🇹🇭
Institute of Dermatology, Bangkok, Thailand
Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2018-12-07
- Target Recruit Count
- 150
- Registration Number
- NCT03764605
- Locations
- 🇮🇹
AOUC "Policlinico", Bari, Italy
🇮🇹AOUConsorziale Policlinico Di Bari, Bari, Italy
Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial
- First Posted Date
- 2018-11-13
- Last Posted Date
- 2018-11-13
- Lead Sponsor
- Globe Pharmaceuticals Limited
- Target Recruit Count
- 30
- Registration Number
- NCT03738956
- Locations
- 🇧🇩
Bangabandhu sheikh mujib medical university, Dhaka, Bangladesh
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.